Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HARMONY BIOSCIENCES HOLDINGS, INC.

(HRMY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/21/2021 07/22/2021 07/23/2021 07/26/2021 07/27/2021 Date
29.55(c) 29.37(c) 29.43(c) 26.72(c) 25.66 Last
251 802 619 969 131 263 289 704 115 529 Volume
+2.82% -0.61% +0.20% -9.21% -3.97% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 301 M - -
Net income 2021 60,1 M - -
Net Debt 2021 44,2 M - -
P/E ratio 2021 26,8x
Yield 2021 -
Sales 2022 528 M - -
Net income 2022 183 M - -
Net cash position 2022 88,5 M - -
P/E ratio 2022 8,92x
Yield 2022 -
Capitalization 1 520 M 1 520 M -
EV / Sales 2021 5,20x
EV / Sales 2022 2,71x
Nbr of Employees 150
Free-Float 81,2%
More Financials
Company
Harmony Biosciences Holdings, Inc. is a holding company. The Company through its subsidiary, Harmony Biosciences, LLC., operates as a pharmaceutical company, which is focused on therapies for patients suffering from central nervous system disorders living with medical needs. It provides treatment options for people living with rare and orphan diseases, with an emphasis on central nervous system disorders, patients... 
Sector
Pharmaceuticals
Calendar
11/18Earnings Release
More about the company
Ratings of Harmony Biosciences Holdings, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about HARMONY BIOSCIENCES HOLDINGS, INC.
07:31aHARMONY BIOSCIENCES : Announces Date Of Second Quarter 2021 Financial Results
PR
06/29HARMONY BIOSCIENCES : Initiates Phase 2 Trial of Pitolisant to Treat Excessive D..
MT
06/29HARMONY BIOSCIENCES : Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
PR
06/29Harmony Biosciences Initiates A Phase 2 Clinical Trial in Myotonic Dystrophy
CI
06/25HARMONY BIOSCIENCES HOLDINGS, INC.(N : HRMY) dropped from Russell 2000 Value Ind..
CI
06/25HARMONY BIOSCIENCES HOLDINGS, INC.(N : HRMY) dropped from Russell 2500 Value Ind..
CI
06/25HARMONY BIOSCIENCES HOLDINGS, INC.(N : HRMY) dropped from Russell 3000E Value In..
CI
06/25HARMONY BIOSCIENCES HOLDINGS, INC.(N : HRMY) dropped from Russell 3000 Value Ind..
CI
06/25HARMONY BIOSCIENCES HOLDINGS, INC.(N : HRMY) dropped from Russell Small Cap Comp..
CI
06/17HARMONY BIOSCIENCES : Development Program for Pitolisant in Patients with Myoton..
PU
06/15HARMONY BIOSCIENCES HOLDINGS, INC. : Change in Directors or Principal Officers (..
AQ
06/10Harmony Biosciences Holdings, Inc. Announces Results of a New Analysis Evalua..
CI
06/10HARMONY BIOSCIENCES : C O R R E C T I O N -- Harmony Biosciences/
PR
06/10HARMONY BIOSCIENCES : Presents new analysis demonstrating the clinical impact of..
PU
06/09HARMONY BIOSCIENCES : Announces Applications for 2021 Patients At The Heart Gran..
PR
More news
News in other languages on HARMONY BIOSCIENCES HOLDINGS, INC.
05/07HBM boucle l'exercice 2020 sur un bénéfice net record
05/07EQS-ADHOC : HBM Healthcare Investments erzielt im Geschäftsjahr 2020/2021 einen ..
More news
Analyst Recommendations on HARMONY BIOSCIENCES HOLDINGS, INC.
More recommendations
Chart HARMONY BIOSCIENCES HOLDINGS, INC.
Duration : Period :
Harmony Biosciences Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HARMONY BIOSCIENCES HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 26,72 $
Average target price 52,00 $
Spread / Average Target 94,6%
EPS Revisions
Managers and Directors
John C.s Jacobs President, Chief Executive Officer & Director
Sandipkumar S. Kapadia Chief Financial Officer
Jeffrey S. Aronin Non-Executive Chairman
Jeffrey M. Dayno Chief Medical Officer
David Bradshaw Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
HARMONY BIOSCIENCES HOLDINGS, INC.-26.09%1 521
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954
ELI LILLY AND COMPANY44.05%221 084